secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001437749-26-004555
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed's neflamapimod selected for UK EXPERTS-ALS platform for ALS trial
--------------------------------------------------------------------------

- Neflamapimod will be evaluated in EXPERTS-ALS, funded by UK NIHR and motor neuron disease charities, costs covered externally.
- Initial phase: ~35 ALS patients for 18-24 weeks measuring neurofilament light chain (NfL) biomarker; potential expansion to 80.
- First patient with ALS expected to be dosed by end of 2026; trial sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.
- CervoMed maintains primary focus on dementia with Lewy bodies (DLB); Phase 3 in DLB planned to start later in 2026.
- Inclusion based on neflamapimod's p38 inhibition, ability to cross BBB, and positive prior clinical safety/biomarker data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926004555/0001437749-26-004555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926004555/crvo20260218_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-004555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer